Low-profile reduced pressure treatment system

Information

  • Patent Grant
  • 8377017
  • Patent Number
    8,377,017
  • Date Filed
    Thursday, January 3, 2008
    17 years ago
  • Date Issued
    Tuesday, February 19, 2013
    11 years ago
Abstract
A low-profile reduced pressure treatment apparatus and system are provided. The apparatus includes a moldable conduit holder, a conduit through the conduit holder, and a flexible base. The conduit holder has first and second bulkhead surfaces, a convex top surface, and a bottom surface adapted to conform to a tissue contact region adjacent to a tissue site. An end of the conduit is substantially flush with the first bulkhead surface and a longitudinal axis of the conduit is substantially perpendicular to the first and second bulkhead surfaces. The base is connected on a first side to the bottom surface of the conduit holder, and extends beyond the first bulkhead surface to form an overlay zone adjacent the first bulkhead surface. An adhesive is disposed on a second side of the flexible base to secure the flexible base to the tissue contact region.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates generally to tissue treatment systems and in particular to low-profile reduced pressure treatment systems.


2. Description of Related Art


Clinical studies and practice have shown that providing a reduced pressure in proximity to a tissue site augments and accelerates the growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but application of reduced pressure has been particularly successful in treating wounds. This treatment (frequently referred to in the medical community as “negative pressure wound therapy,” “reduced pressure therapy,” or “vacuum therapy”) provides a number of benefits, including faster healing and increased formulation of granulation tissue. Typically, reduced pressure is applied to tissue through a porous pad or other manifolding device. The porous pad contains cells or pores that are capable of distributing reduced pressure to the tissue and channeling fluids that are drawn from the tissue. The porous pad often is incorporated into a dressing having other components that facilitate treatment.


Traditionally, dressings have been rather cumbersome and difficult to apply to small wounds. Simply sitting on or rolling onto a dressing may cause significant patient discomfort, or pressure-induced injury, particularly at contact with relatively stiff components such as tubing connections, elbows, and other components. Moreover, these actions may compress the dressing and interfere with the application of reduced pressure. Furthermore, the profile of these dressings and any protuberances present the likelihood of snagging on patient clothing or surroundings during normal activity, a risk associated with pain and possible re-injury of tissue.


Accordingly, there is much demand for improved dressings that alleviate the disadvantages of known dressings.


All references cited herein are incorporated by reference to the maximum extent allowable by law. To the extent a reference may not be fully incorporated herein, it is incorporated by reference for background purposes and indicative of the knowledge of one of ordinary skill in the art.


BRIEF SUMMARY OF THE INVENTION

The problems presented in known reduced pressure treatment systems are solved by the systems and methods of the present invention. A low-profile reduced pressure treatment apparatus and system are provided in accordance with the principles of the present invention.


One embodiment of the low-profile reduced pressure treatment apparatus includes a moldable conduit holder, a conduit extending through the conduit holder, and a flexible base. The conduit holder has substantially parallel first and second bulkhead surfaces, a convex top surface, and a bottom surface adapted to substantially conform in shape to a tissue contact region adjacent to a tissue site. The conduit extends through the conduit holder such that an end of the conduit is substantially flush with the first bulkhead surface and a longitudinal axis of the conduit is substantially perpendicular to the first and second bulkhead surfaces. The flexible base has a first side connected to the bottom surface of the conduit holder, the flexible base extending beyond the first bulkhead surface to form an overlay zone adjacent the first bulkhead surface. An adhesive is disposed on a second side of the flexible base to secure the flexible base to the tissue contact region.


An embodiment of the low-profile reduced pressure treatment system includes a moldable conduit holder, a conduit received by the conduit holder, a base, a porous pad, a drape, and a reduced pressure source fluidly connected to the conduit to deliver reduced pressure through the conduit and the porous pad. The conduit holder has substantially parallel first and second bulkhead surfaces, a convex top surface, and a bottom surface adapted to substantially conform in shape to a tissue contact region adjacent to a tissue site. The conduit is received by the conduit holder such that an end of the conduit is substantially flush with the first bulkhead surface and a longitudinal axis of the conduit is substantially perpendicular to the first and second bulkhead surfaces. The base has a first side connected to the bottom surface of the conduit holder, the base extending beyond the first bulkhead surface to form an overlay zone adjacent the first bulkhead surface. An adhesive is disposed on a second side of the base to secure the base to the tissue contact region adjacent to the tissue site. The porous pad includes a primary delivery region configured to contact the tissue site and a bridge region configured to contact the overlay zone of the base and apply a flexible transition to the tissue site. The drape is sized to cover and create a sealed space around the conduit holder and the porous pad.


Also in accordance with the principles of the present invention, a process for making and using a low-profile reduced pressure treatment apparatus and system is provided. One embodiment for making a low-profile reduced pressure treatment apparatus includes positioning a first flexible membrane on an arcuate form, positioning a conduit on the first flexible membrane, extruding silicone onto and around the conduit, positioning a second flexible membrane over the silicone and the conduit, securing edges of the second flexible membrane to edges of the first flexible membrane, and securing the first flexible membrane to a drape having dimensions greater than the first flexible membrane so that the drape extends beyond the edges of the first flexible membrane adjacent to an aperture of the conduit.


One process for using a low-profile reduced pressure treatment apparatus includes positioning a first flexible membrane so that an overlay zone is adjacent to the tissue site and a conduit holder is adjacent to the overlay zone opposite the tissue site; positioning a porous pad so that a bridge region is aligned with the overlay zone and a primary delivery region is aligned with the tissue site; connecting the porous pad to a reduced pressure source through a conduit in the conduit holder; positioning a second flexible membrane over the conduit holder and the porous pad; sealing the second flexible membrane to the tissue contact region; and applying reduced pressure from the reduced pressure source to the tissue site through the conduit and the porous pad.


Other objects, features, and advantages of the present invention will become apparent with reference to the drawings and detailed description that follow.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates a schematic view of a reduced pressure treatment system according to the present invention;



FIG. 2 illustrates an exploded view of a low-profile adapter according to the present invention;



FIG. 3 illustrates a perspective view of the assembled low-profile adapter of FIG. 2 according to the present invention;



FIG. 4 illustrates a perspective view of the assembled low-profile adapter of FIG. 3 with a porous pad in position over a bridge overlay zone according to the present invention;



FIG. 5 illustrates a perspective view of the assembled low-profile adapter of FIG. 3 with an alternate embodiment of the porous pad according to the present invention;



FIG. 6 illustrates a perspective view of the assembled low-profile adapter and porous pad of FIG. 4 covered by a drape according to the present invention;



FIG. 7 illustrates a perspective view of an alternate embodiment of a low-profile adapter having multiple conduits according to the present invention; and



FIG. 8 illustrates a front view of an alternate embodiment of a low-profile adapter having a concave molded base according to the present invention.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

In the following detailed description of the preferred embodiments, reference is made to the accompanying drawings that form a part hereof, and in which is shown by way of illustration specific preferred embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the invention, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined only by the appended claims.


In the context of this specification, the term “reduced pressure” generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure of the location at which the patient is located. Although the terms “vacuum” and “negative pressure” may be used to describe the pressure applied to the tissue site, the actual pressure applied to the tissue site may be significantly less than the pressure normally associated with a complete vacuum. Consistent with this nomenclature, an increase in reduced pressure or vacuum pressure refers to a relative reduction of absolute pressure, while a decrease in reduced pressure or vacuum pressure refers to a relative increase of absolute pressure.



FIG. 1 is a schematic diagram of a reduced pressure treatment system 100 incorporating the novel features of the invention. The reduced pressure treatment system 100 comprises a dressing 110, which is applied to a tissue site 120 for treatment. Dressing 110 is fluidly connected to a reduced pressure source 120 by a conduit 130. In certain embodiments, the reduced pressure system 110 may also include a canister 140 for collecting liquid and other non-gaseous exudates extracted from a tissue site.



FIG. 2 is an exploded view of an embodiment of a low-profile adapter 200. In this embodiment, the adapter 200 comprises a conduit holder 205, a first bulkhead surface 215, and a second bulkhead surface 220 that is substantially parallel to the first bulkhead surface 215. In this embodiment, the conduit holder 205 has a convex top surface 210 to minimize the profile of the conduit holder 205. The conduit holder 205 also includes a conduit 225 that extends through the length of the conduit holder 205, having an aperture 230 on the first bulkhead surface 215 and an aperture 235 on the second bulkhead surface 220.


The conduit holder 205 is constructed from any material that may be extruded or injected into a mold, such as room temperature vulcanizing (RTV) silicone. The conduit 130 may be inserted into or connected to the conduit 225 to establish a fluid path between the aperture 230 and the reduced pressure source 120.


Depending on the composition of the conduit holder 205, the conduit holder 205 may optionally be enclosed between flexible membranes of a material more suitable for tissue contact, such as a nitrile film, as illustrated by the flexible membranes 240 and 245. In such an embodiment, the flexible membrane 245 is attached to the flexible membrane 250.


Alternatively, the flexible membrane 245 may be omitted and the flexible membrane 240 may be attached directly to the flexible membrane 250. The flexible membrane 250 is preferably a polyurethane material. A drape 255 having adhesive surface 256 is bonded to the flexible membrane 250 on one side. The drape 255 may include an optional biocompatible adhesive surface 257 on the side opposite the adhesive surface 256. The biocompatible adhesive surface 257 may consist of any suitable bonding agent, such as an acrylic adhesive or hydrogel. The biocompatible adhesive surface 257 may be applied to intact tissue to secure the low-profile adapter in position when applied to a tissue site. If the drape 255 includes the biocompatible adhesive surface 257, a protective liner 260 is applied to the biocompatible adhesive surface 257 to preserve the adhesive and facilitate handling. The protective liner 260 is removed to expose the underlying adhesive before application to the tissue site 120. The flexible membrane 250, the drape 255, and optionally, the protective liner 260 comprise a base 265. The drape 255 generally is constructed from any flexible material having a sufficiently high moisture vapor transmission rate (MTVR) to preclude tissue maceration, typically greater than 600 mg/m2/day. Polyurethane is an example of a suitable material for the drape 255. Because of the flexibility of the flexible membrane 250 and the drape 255, the base 265 readily conforms to the contours of most tissue sites.



FIG. 3 is a perspective view of the assembled low-profile adapter 200. The conduit holder 205 has a height h, as measured between the apex of the first bulkhead surface 215 and the base 265. As FIG. 3 illustrates, the base 265 extends beyond the first bulkhead surface 215 to form a bridge overlay zone 300 adjacent to the first bulkhead surface 215 and the aperture 230.



FIG. 4 is a perspective view of the assembled low-profile adapter 200 with a porous pad 400 in position over the bridge overlay zone 300 (not visible in FIG. 4). The porous pad 400 generally includes a porous bridge 402 and a primary delivery region 404. FIG. 4 also illustrates a section of the conduit 130, which is connected on one end to the aperture 235 (not shown in FIG. 4). The porous pad 400 has a thickness, t, sufficient to cover the aperture 230 in the first bulkhead surface 215, which is typically the same dimension as the height h of the conduit holder 205. The porous pad 400 also has a depth d sufficient to extend from the first bulkhead surface 215 and overhang the bridge overlay zone 300 to cover a tissue site. FIG. 4 also illustrates an optional porous extension 405, which may be inserted into a tissue site for deeper penetration. Although the porous extension 405 is depicted in FIG. 4 as a separate component, the porous extension 405 may be an integral component of the porous pad 400 so that the porous pad 400 and the porous extension 405 form a single component. Likewise, the porous pad 400 and the porous extension 405 are illustrated as simple block pieces, but they may be adapted to any desired shape. For example, the porous pad 400 may be cut to conform to the profile of the conduit holder 205 or to the shape of an irregular tissue site.


The porous pad 400 and the porous extension 405 represent any material known in the art to be suitable for reduced pressure treatment, the size and shape of which may be varied to accommodate tissue sites of various size and shape. Preferably, the porous pad 400 and the porous extension 405 include a plurality of flow channels or pathways to facilitate the distribution of reduced pressure or fluids to or from the tissue site. In one embodiment, the porous pad 400 and the porous extension 405 are porous foam that includes interconnected cells or pores that act as flow channels and a pressure manifold. The porous foam may be polyurethane or any other type of open-cell, reticulated foam, such as GRANUFOAM manufactured by Kinetic Concepts, Inc. of San Antonio, Tex. If open-cell foam is used, the porosity may vary, but is preferably about 400 to 600 microns. Alternatively, gauze or any other material suited to a particular biological application may be used to construct the porous pad 400 and the porous extension 405.



FIG. 5 is a perspective view of the low-profile adapter 200 with an alternative embodiment of a porous pad. As FIG. 5 illustrates, a porous pad may be comprised of one or more discrete components, such as a porous bridge 502 and a primary delivery component 504. Such an alternative embodiment may be advantageous for packaging a universal bridge component with the low-profile adapter 200, while permitting additional components to be fit to a particular tissue site as needed.



FIG. 6 is a perspective view of the low-profile adapter 200, a porous pad 400, and a drape 600. The drape 600 covers the low-profile adapter 200 and the porous pad 400, and includes an adhesive on the surface 605 that is applied to a tissue contact region adjacent to a subject tissue site (not shown). The adhesive may consist of any suitable bonding agent, such as an acrylic adhesive or hydrogel. The seal isolates the tissue site from the surrounding environment and assists in maintaining a reduced pressure at the tissue site when reduced pressure is applied. The convex top surface 210 provide tapered lateral edges, which minimize the risk of leaks between the drape 600 and the tissue contact region adjacent to the tissue site. The adhesive may also secure the low-profile adapter 200 and the porous pad 400 in position if the drape 255 does not include the optional biocompatible adhesive surface 257. Like the drape 255, the drape 600 generally is constructed from any flexible material having a sufficiently high moisture vapor transmission rate (MTVR) to preclude tissue maceration, typically greater than 600 mg/m2/day.


In operation, the protective liner 260 (if present) is removed to expose the adhesive surface 257 (if present), and the low-profile adapter 200 is positioned so that the bridge overlay zone 300 is over intact tissue and immediately adjacent to a tissue site 120. A porous pad (such as porous pad 400) is positioned so that it extends from the first bulkhead surface 215 and overhangs the bridge overlay zone 300 to cover the tissue site 120, while one end covers the aperture 230 in the first bulkhead surface 215. The drape 600 is then placed over the low-profile adapter 200 and the porous pad 400, and the edges of the drape 600 are pressed against intact tissue surrounding the low-profile adapter 200 and the intact tissue surrounding the tissue site 120. The conduit 130 is then connected on one end to the conduit 225 through the aperture 235 in the second bulkhead surface 220, and on the other end to the collection canister 140 or the reduced pressure source 125. Reduced pressure may then be delivered to the tissue site 120 through the conduit 130, the conduit 225, and the pad 400.



FIG. 7 is a perspective view of an alternate embodiment of a low-profile adapter 700. In this embodiment, the adapter 700 comprises a conduit holder 705 having a convex top surface 710, a first bulkhead surface 715, and a second bulkhead surface 720 that is substantially parallel to the first bulkhead surface 715. The conduit holder 705 also includes two conduits 725 and 730 that extend through the length of the conduit holder 705, having two apertures 735 and 740 on the first bulkhead surface 715, and two apertures 745 and 750 on the second bulkhead surface 720. Multiple conduits, such as those depicted in FIG. 7, may be advantageous for applications such as pressure monitoring and fluid distribution in conjunction with reduced pressure application. Alternatively, a multi-lumen conduit may be substituted for any pair of conduits.



FIG. 8 is a front view of another alternate embodiment of a low-profile adapter 800. In this embodiment, the low-profile adapter 800 comprises a conduit holder 805 having a convex top surface 810, a first bulkhead surface 815, and a second bulkhead surface (not shown) that is substantially parallel to the first bulkhead surface 815. The conduit holder 805 also includes a conduit (not shown) that extends through the length of the conduit holder 805, having an aperture 830 on the first bulkhead surface 815 and an aperture (not shown) on the second bulkhead surface (not shown). The conduit holder 805 is attached to a base 835 that is molded to conform to the contours of a particular tissue site, such as on a finger or other limb. The base 835 in such an embodiment may be constructed from any material that may be extruded or injected into a mold, such as room temperature vulcanizing (RTV) silicone, or from any biocompatible material that is readily manipulated at room temperature.


A low-profile adapter embodying the principles and features described above may generally be constructed as follows, referring to the embodiment described above as the low-profile adapter 200 having the flexible membranes 240 and 245 for illustration. First, the flexible membranes 240 and 245 are cut into substantially equal shapes and sizes, and the flexible membrane 245 is anchored or placed onto a form of desired contour or shape. For the low-profile adapter 200, the form should be substantially flat, but the form may have a convex surface to form alternate embodiments such as the low-profile adapter 800. The conduit 225 is then positioned across the flexible membrane 245. The material of the conduit holder 205 is then extruded onto and around the conduit 225, forming the first bulkhead surface 215 and the second bulkhead surface 220 around each end of the conduit 225 so that the aperture 230 is substantially flush with the first bulkhead surface 215 and the aperture 235 is substantially flush with the second bulkhead surface 220. The material should be shaped to form the convex top surface 210. The flexible membrane 240 is then stretched across the conduit 225 and the surrounding material, and the edges of the flexible membrane 240 are secured to the edges of the flexible membrane 245 using any adhesive, bonding agent, thread, staples, or other suitable means. The drape 255 is prepared by sizing it so that a border of desired width extends laterally and in front of the conduit holder 205. For small tissue sites, the border width may be on the order of 1 cm. Allowing time for the material surrounding the conduit 225 to cure, if necessary, the flexible membrane 245 is placed on the adhesive surface 256 of the drape 255. The flexible membrane 250 is placed around the conduit holder 225 to cover any exposed adhesive on the adhesive surface 256. Finally, the protective liner is applied to the adhesive surface 257, if desired.


One skilled in the art will see that the present invention can be applied in many areas where there is a need to provide tissue treatment. For example, the shape of the low-profile adapter may be changed to accommodate anatomical features, as well as flat, convex, or saddle-shaped skin contours. Likewise, the shape and dimensions of the porous bridge may be altered to accommodate various sizes and shapes of tissue sites. Additionally, multiple low-profile adapters may be used in series using small conduits and interconnecting ports, which may be advantageous for hardware penetration points of orthopedic external fixation.


It should be apparent from the foregoing that an invention having significant advantages has been provided. While the invention is shown in only a few of its forms, it is not so limited and is susceptible to various changes and modifications without departing from the spirit thereof.

Claims
  • 1. A reduced pressure treatment system comprising: a moldable conduit holder having substantially parallel first and second bulkhead surfaces, a bottom surface, and a convex top surface, the bottom surface adapted to substantially conform in shape to a tissue contact region adjacent to a tissue site;a conduit having a first portion received by the second bulkhead surface and a second portion extending longitudinally through the conduit holder to the first bulkhead surface and substantially perpendicular to the first and second bulkhead surfaces;a base having a side connected to the bottom surface of the conduit holder, the base extending beyond the first bulkhead surface to form a bridge overlay zone adjacent the first bulkhead surface;a porous pad having a primary delivery region configured to contact the tissue site and a porous bridge region having a side surface configured to contact the first bulkhead surface in fluid communication with the conduit and a bottom surface connected to the bridge overlay zone of the base;a drape sized to create a sealed space around and cover the first portion of the conduit, the conduit holder, and the porous pad, wherein the conduit is substantially parallel to the tissue contact region; anda reduced pressure source fluidly connected to the conduit to deliver reduced pressure through the conduit and the porous bridge region to the primary delivery region of the porous pad.
  • 2. The system of claim 1, wherein the conduit holder is formed from room-temperature-vulcanizing silicone.
  • 3. The system of claim 1, wherein the base is adhesively connected to the bottom surface of the conduit holder.
  • 4. The system of claim 1, further comprising a second conduit positioned adjacent the first conduit such that an end of the second conduit is substantially flush with the first bulkhead surface and a longitudinal axis of the second conduit is substantially perpendicular to the first and second bulkhead surfaces.
  • 5. The system of claim 1, wherein the conduit holder further comprises: a first flexible membrane forming the bottom surface;a second flexible membrane forming the top surface; anda moldable material disposed between the first and second flexible membranes to encase the conduit between the first and second flexible membranes.
  • 6. The system of claim 5, wherein the first and second membranes are nitrile film.
  • 7. The system of claim 1, further comprising a porous extension region oriented adjacent to the primary delivery region so that the porous extension region extends into the tissue site.
  • 8. The system of claim 1, wherein the side surface of the porous bridge region has substantially the same cross-sectional shape as the first bulkhead surface.
  • 9. The system of claim 1, wherein the porous pad has a thickness and the conduit holder has a height that are substantially equal.
  • 10. The system of claim 1, wherein the porous pad has a top surface facing the drape which is substantially coplanar with the convex top surface of the conduct holder.
  • 11. The system of claim 1, wherein the side surface of the porous bridge region is substantially perpendicular to the tissue site.
  • 12. The system of claim 1, wherein the primary delivery region and the porous bridge region as separate components, each having a contact surface in fluid communication with each others contact surface.
  • 13. The system of claim 12, wherein the porous bridge region and the primary delivery region each have a top surface facing the drape that are substantially coplanar.
  • 14. The system of claim 12, wherein the porous bridge region has a top surface facing the drape which is substantially coplanar with the convex top surface of the conduit holder.
  • 15. The system of claim 1, wherein: the primary delivery region of the porous pad is a first manifold positioned in contact with the tissue site for distributing reduced pressure to the tissue site; andthe porous bridge region of the porous pad is a second manifold positioned in fluid communication with the first manifold for distributing reduced pressure to the tissue site.
US Referenced Citations (189)
Number Name Date Kind
1355846 Rannells Oct 1920 A
2547758 Keeling Apr 1951 A
2632443 Lesher Mar 1953 A
2682873 Evans et al. Jul 1954 A
2910763 Lauterbach Nov 1959 A
2969057 Simmons Jan 1961 A
3066672 Crosby, Jr. et al. Dec 1962 A
3367332 Groves Feb 1968 A
3376868 Mondiadis Apr 1968 A
3520300 Flower, Jr. Jul 1970 A
3568675 Harvey Mar 1971 A
3648692 Wheeler Mar 1972 A
3682180 McFarlane Aug 1972 A
3742952 Magers et al. Jul 1973 A
3763857 Schrading Oct 1973 A
3774611 Tussey et al. Nov 1973 A
3779243 Tussey et al. Dec 1973 A
3826254 Mellor Jul 1974 A
4080970 Miller Mar 1978 A
4096853 Weigand Jun 1978 A
4139004 Gonzalez, Jr. Feb 1979 A
4141361 Snyder Feb 1979 A
4165748 Johnson Aug 1979 A
4184510 Murry et al. Jan 1980 A
4233969 Lock et al. Nov 1980 A
4245630 Lloyd et al. Jan 1981 A
4256109 Nichols Mar 1981 A
4261363 Russo Apr 1981 A
4275721 Olson Jun 1981 A
4284079 Adair Aug 1981 A
4297995 Golub Nov 1981 A
4333468 Geist Jun 1982 A
4373519 Errede et al. Feb 1983 A
4382441 Svedman May 1983 A
4392853 Muto Jul 1983 A
4392858 George et al. Jul 1983 A
4419097 Rowland Dec 1983 A
4465485 Kashmer et al. Aug 1984 A
4475909 Eisenberg Oct 1984 A
4480638 Schmid Nov 1984 A
4525166 Leclerc Jun 1985 A
4525374 Vaillancourt Jun 1985 A
4529402 Weilbacher et al. Jul 1985 A
4540412 Van Overloop Sep 1985 A
4543100 Brodsky Sep 1985 A
4548202 Duncan Oct 1985 A
4551139 Plaas et al. Nov 1985 A
4569348 Hasslinger Feb 1986 A
4605399 Weston et al. Aug 1986 A
4608041 Nielsen Aug 1986 A
4640688 Hauser Feb 1987 A
4655754 Richmond et al. Apr 1987 A
4664652 Weilbacher May 1987 A
4664662 Webster May 1987 A
4710165 McNeil et al. Dec 1987 A
4733659 Edenbaum et al. Mar 1988 A
4743232 Kruger May 1988 A
4758220 Sundblom et al. Jul 1988 A
4787888 Fox Nov 1988 A
4826494 Richmond et al. May 1989 A
4838883 Matsuura Jun 1989 A
4840187 Brazier Jun 1989 A
4841962 Berg et al. Jun 1989 A
4863449 Therriault et al. Sep 1989 A
4872450 Austad Oct 1989 A
4878901 Sachse Nov 1989 A
4897081 Poirier et al. Jan 1990 A
4906233 Moriuchi et al. Mar 1990 A
4906240 Reed et al. Mar 1990 A
4919654 Kalt Apr 1990 A
4941882 Ward et al. Jul 1990 A
4953565 Tachibana et al. Sep 1990 A
4969880 Zamierowski Nov 1990 A
4981474 Bopp et al. Jan 1991 A
4985019 Michelson Jan 1991 A
5000164 Cooper Mar 1991 A
5037397 Kalt et al. Aug 1991 A
5086170 Luheshi et al. Feb 1992 A
5092858 Benson et al. Mar 1992 A
5100396 Zamierowski Mar 1992 A
5112323 Winkler et al. May 1992 A
5134994 Say Aug 1992 A
5149331 Ferdman et al. Sep 1992 A
5167613 Karami et al. Dec 1992 A
5176663 Svedman et al. Jan 1993 A
5215522 Page et al. Jun 1993 A
5215539 Schoolman Jun 1993 A
5232453 Plass et al. Aug 1993 A
5261893 Zamierowski Nov 1993 A
5278100 Doan et al. Jan 1994 A
5279550 Habib et al. Jan 1994 A
5298015 Komatsuzaki et al. Mar 1994 A
5342329 Croquevielle Aug 1994 A
5342376 Ruff Aug 1994 A
5344415 DeBusk et al. Sep 1994 A
5358494 Svedman Oct 1994 A
5437622 Carion Aug 1995 A
5437651 Todd et al. Aug 1995 A
5449379 Hadtke Sep 1995 A
5527293 Zamierowski Jun 1996 A
5549584 Gross Aug 1996 A
5556375 Ewall Sep 1996 A
5607388 Ewall Mar 1997 A
5636643 Argenta et al. Jun 1997 A
5645081 Argenta et al. Jul 1997 A
5688225 Walker Nov 1997 A
5784811 Mauch Jul 1998 A
5809665 Suenaga Sep 1998 A
5913838 Reilly Jun 1999 A
6071267 Zamierowski Jun 2000 A
6129692 Mathis Oct 2000 A
6135116 Vogel et al. Oct 2000 A
6174306 Fleischmann Jan 2001 B1
6178662 Legatzke Jan 2001 B1
6241747 Ruff Jun 2001 B1
6287316 Agarwal et al. Sep 2001 B1
6290685 Insley et al. Sep 2001 B1
6345623 Heaton et al. Feb 2002 B1
6360457 Qui et al. Mar 2002 B1
6361512 Mackay et al. Mar 2002 B1
6425194 Brie Jul 2002 B1
6471685 Johnson Oct 2002 B1
6488643 Tumey et al. Dec 2002 B1
6493568 Bell et al. Dec 2002 B1
6553998 Heaton et al. Apr 2003 B2
6626891 Ohmstede Sep 2003 B2
6631568 Howlett et al. Oct 2003 B2
6663610 Thompson et al. Dec 2003 B1
6685681 Lockwood et al. Feb 2004 B2
6695824 Howard et al. Feb 2004 B2
6736787 McEwen et al. May 2004 B1
6752794 Lockwood et al. Jun 2004 B2
6814079 Heaton et al. Nov 2004 B2
6855135 Lockwood et al. Feb 2005 B2
6979324 Bybordi et al. Dec 2005 B2
7070584 Johnson et al. Jul 2006 B2
7207977 Thompson et al. Apr 2007 B2
7279612 Heaton et al. Oct 2007 B1
7282038 Gillis et al. Oct 2007 B2
7880050 Robinson et al. Feb 2011 B2
20010000262 McEwen et al. Apr 2001 A1
20010031943 Urie Oct 2001 A1
20010043943 Coffey Nov 2001 A1
20020017304 Heaton et al. Feb 2002 A1
20020065494 Lockwood et al. May 2002 A1
20020077661 Saadat Jun 2002 A1
20020082567 Lockwood et al. Jun 2002 A1
20020115951 Norstrem et al. Aug 2002 A1
20020115952 Johnson et al. Aug 2002 A1
20020120185 Johnson Aug 2002 A1
20020143286 Tumey Oct 2002 A1
20020150720 Howard et al. Oct 2002 A1
20020178499 Augustine et al. Dec 2002 A1
20020198504 Risk, Jr. et al. Dec 2002 A1
20030050594 Zamierowski Mar 2003 A1
20030061733 Karsten Apr 2003 A1
20030125649 McIntosh et al. Jul 2003 A1
20030176828 Buckman et al. Sep 2003 A1
20030216672 Rastegar et al. Nov 2003 A1
20040030304 Hunt et al. Feb 2004 A1
20040064132 Boehringer et al. Apr 2004 A1
20050004534 Lockwood et al. Jan 2005 A1
20050020955 Sanders et al. Jan 2005 A1
20050027218 Filtvedt et al. Feb 2005 A1
20050070858 Lockwood et al. Mar 2005 A1
20050101940 Radl et al. May 2005 A1
20050137539 Biggie et al. Jun 2005 A1
20050228329 Boehringer et al. Oct 2005 A1
20050261642 Weston Nov 2005 A1
20050261643 Bybordi et al. Nov 2005 A1
20060100556 Hargens et al. May 2006 A1
20060100586 Karpowicz et al. May 2006 A1
20060149171 Vogel et al. Jul 2006 A1
20060155260 Blott et al. Jul 2006 A1
20060189909 Hurley et al. Aug 2006 A1
20060189910 Johnson et al. Aug 2006 A1
20060287621 Atkinson et al. Dec 2006 A1
20070027414 Hoffman et al. Feb 2007 A1
20070060848 Erdmann Mar 2007 A1
20070124959 Meffan Jun 2007 A1
20070167884 Mangrum et al. Jul 2007 A1
20070185426 Ambrosio et al. Aug 2007 A1
20070218101 Johnson et al. Sep 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070265585 Joshi et al. Nov 2007 A1
20070265586 Joshi et al. Nov 2007 A1
20080047164 Vindriis Feb 2008 A1
20080066343 Sanabria-Hernandez Mar 2008 A1
20080071234 Kelch et al. Mar 2008 A1
Foreign Referenced Citations (51)
Number Date Country
550575 Aug 1982 AU
745271 Apr 1999 AU
755496 Feb 2002 AU
2005436 Jun 1990 CA
26 40 413 Mar 1978 DE
43 06 478 Sep 1994 DE
295 04 378 Oct 1995 DE
19844355 Apr 2000 DE
10 2004 055 702 Nov 2005 DE
0100148 Feb 1984 EP
0117632 Sep 1984 EP
0161865 Nov 1985 EP
0358302 Mar 1990 EP
1018967 Aug 2004 EP
1872763 Jan 2008 EP
692578 Jun 1953 GB
2 195 255 Apr 1988 GB
2 197 789 Jun 1988 GB
2 220 357 Jan 1990 GB
2 235 877 Mar 1991 GB
2 333 965 Aug 1999 GB
2 329 127 Aug 2000 GB
2415908 Jan 2006 GB
4129536 Apr 1992 JP
2003-532504 Nov 2003 JP
71559 Apr 2002 SG
WO 8002182 Oct 1980 WO
WO 8704626 Aug 1987 WO
WO 8801499 Mar 1988 WO
WO 9010424 Sep 1990 WO
WO 9309727 May 1993 WO
WO 9420041 Sep 1994 WO
WO 9605873 Feb 1996 WO
WO 9606559 Mar 1996 WO
WO 9718007 May 1997 WO
WO 9913793 Mar 1999 WO
WO 0059424 Oct 2000 WO
WO 0064394 Nov 2000 WO
WO 0185248 Nov 2001 WO
WO 0189431 Nov 2001 WO
WO 03057307 Jul 2003 WO
WO 03099188 Dec 2003 WO
WO 2004018020 Mar 2004 WO
WO 2005123170 Dec 2005 WO
WO 2006087021 Aug 2006 WO
WO 2007092397 Aug 2007 WO
WO 2007133618 Nov 2007 WO
WO 2008036361 Mar 2008 WO
WO 2008057600 May 2008 WO
WO 2008100440 Aug 2008 WO
WO 2008100446 Aug 2008 WO
Non-Patent Literature Citations (85)
Entry
N. A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of the Soft Tissues,” Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986);pp. 94-96 (certified translation).
K.F. Jeter, T.E. Tintle, and M. Chariker, Managing Draining Wounds and Fistulae: “New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246.
G. {hacek over (Z)}ivadinović, V. ukić, {hacek over (Z)}. Maksimović, Radak, and P. Pe{hacek over (s)}ka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164 (certified translation).
F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585.
A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967 (certified translation).
M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370.
“D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction,” Archives of Surgery 105 (1972) pp. 511-513.
M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I).
C.E. Tennants, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax, ”Journal of the American Medical Association 64 (1915), pp. 1548-1549.
Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211.
NPD 1000 Negative Pressure Wound Therapy System, Kalypto Medical, pp. 1-4.
Louis C. Argenta, MD and Michael J. Morykwas, PhD; “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience”; Annals of Plastic Surgery, vol. 38, No. 6, Jun. 1997; pp. 563-576.
Susan Mendez-Eastmen, RN; “When Wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24.
James H. Blackburn, II, MD, et al; “Negative-Pressure Dressings as a Bolster for Skin Grafts”; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457.
John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letter to the Editor, British Journal of Plastic Surgery, 1998, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK.
S.E. Greer, et al “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin” British Journal of Plastic Surgery (2000), 53, pp. 484-487.
George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, 31, 1990, pp. 634-639.
Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80.
International Search Report for PCT International Application PCT/GB95/01983; Nov. 23, 1995.
PCT International Search Report for PCT International Application PCT/GB98/02713; Jan. 8, 1999.
PCT Written Opinion; PCT International Application PCT/GB98/02713; Jun. 8, 1999.
PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; Jan. 15, 1998 & Apr. 29, 1997.
PCT Written Opinion, PCT International Application PCT/GB96/02802; Sep. 3, 1997.
Dattilo, Philip P., Jr., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5.
Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof.
Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof.
Yusupov. Yu. N., et al; “Active Wound Drainage”, Vestnik Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof.
Davydov, Yu. A., et al; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirurgi, Oct. 1988, pp. 48-52, and 8 page English translation thereof.
Davydov, Yu. A., et al; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof.
Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63.
Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24.
Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2.
Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534.
Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81.
Arnljots, Björn et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., No. 19, 1985, pp. 211-213.
Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221.
Svedman, P. et al.: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133.
International Search Report and Written Opinion date mailed Feb. 19, 2009; PCT Application No. PCT/US2008/088635.
V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”).
V.A. Kuznetsov & N.a. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”).
V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”).
Notice of Appeal filed Jun. 14, 2010 for U.S. Appl. No. 10/895,700.
Appeal Brief filed Jul. 13, 2010 for U.S. Appl. No. 10/895,700.
Response filed Jul. 19, 2010 for U.S. Appl. No. 12/069,245.
Non-final office action date mailed Dec. 16, 2005 for U.S. Appl. No. 10/895,700.
Response filed Jun. 19, 2006 for U.S. Appl. No. 10/895,700.
Notice of Non-Compliant date mailed Sep. 5, 2006 for U.S. Appl. No. 10/895,700.
Response filed Dec. 22, 2006 for U.S. Appl. No. 10/895,700.
Amendment/Request after non-final rejection filed Jan. 19, 2007 for U.S. Appl. No. 10/895,700.
Supplemental response filed Mar. 21, 2007 for U.S. Appl. No. 10/895,700.
Final Office Action date mailed Jun. 11, 2007 for U.S. Appl. No. 10/895,700.
RCE/Response filed Sep. 14, 2007 for U.S. Appl. No. 10/895,700.
Amendment/Request Reconsideration—after non-final rejection filed Jan. 28, 2008 for U.S. Appl. No. 10/895,700.
Non-Final Office Action date mailed Mar. 18, 2008 for U.S. Appl. No. 10/895,700.
Response filed Jun. 17, 2008 for U.S. Appl. No. 10/895,700.
Final Office Action date mailed Sep. 19, 2008 for U.S. Appl. No. 10/895,700.
RCE/Response filed Jan. 21, 2009 for U.S. Appl. No. 10/895,700.
Interview Summary date mailed Mar. 2, 2009 for U.S. Appl. No. 10/895,700.
Supplemental Response filed Mar. 25, 2009 for U.S. Appl. No. 10/895,700.
Non-Final Office Action date mailed May 27, 2009 for U.S. Appl. No. 10/895,700.
Interview Summary date mailed Sep. 4, 2009 for U.S. Appl. No. 10/895,700.
Response filed Oct. 27, 2009 for U.S. Appl. No. 10/895,700.
Final Office Action date mailed Mar. 15, 2010 for U.S. Appl. No. 10/895,700.
Response filed May 14, 2010 to Final Office Action for U.S. Appl. No. 10/895,700.
Advisory Action date mailed May 20, 2010 for U.S. Appl. No. 10/895,700.
Non-Final Office Action date mailed Apr. 27, 2010 for U.S. Appl. No. 12/069,245.
Merriam OnLine definitions—“occlusive”, “occlude” and “occluding” (unknown date).
Arcand, “Negative Pressure Wound Therapy and its Application to Othopaedics. Part II: Clinical Application”, Osteo Trauma Care 2006; 14-254-258.
Culliford, “A Novel Technique for Vacuum Assisted Closure Device Application in Noncontiguous Wounds”, Journal of Plastic, Reconstructive & Aesthetic Surgery 2006.
Armstrong, “Plantar Pressure Changes Using a Novel Negative Pressure Wound Therapy Technique”, Journal of the American Podiatric Medical Association, Sep./Oct. 2004, vol. 94. No. 5, pp. 456-460.
“Guidelines for Managing Pressure Ulcers with Negative Pressure Wound Therapy”, a Supplement of Advances in Skin & Wound Care, vol. 17, Suppl. 2, Nov./Dec. 2004.
Venturi, “Mechanisms and Clinical Applications of the Vacuum-Assisted Closure (VAC) Device”, Am J Clin Dermatol 2005: 6(3): 185-194.
V.A.C.® Therapy Clinical Guidelines: A Reference Source for Clinicians (Jul. 2007)—http://www.kci1.com/Clinical—Guidelines—VAC.pdf, pp. 1-88.
V.A.C.® Therapy Clinical Guidelines: A Reference Source for Clinicians (Jul. 2007)—http://www.kci1.com/Clinical—Guidelines—VAC.pdf, p. 25.
Lavery, Lawrence, et al: “Emerging Concepts with VAC Therapy”; vol. 20, Publication date Jul. 1, 2007, Issue No. 7.
Non-Final Office Action date mailed Aug. 2, 2011 for U.S. Appl. No. 13/015,209.
Response filed Nov. 1, 2011 for U.S. Appl. No. 13/015,209.
Non-Final Office Action date mailed Oct. 18, 2011 for U.S. Appl. No. 12/403,296.
Response filed Nov. 15, 2011 for U.S. Appl. No. 12/403,296.
Notice of Allowance date mailed Nov. 25, 2011 for U.S. Appl. No. 13/015,209.
Notice of Allowance date mailed Jan. 11, 2012 for U.S. Appl. No. 12/403,296.
Examiner's Answer to Appeal Brief Oct. 13, 2010 for U.S. Appl. No. 10/895,700.
Request for Oral Hearing Reply Brief Dec. 6, 2010 for U.S. Appl. No. 10/895,700.
Notice of Allowance date mailed Oct. 1, 2010 for U.S. Appl. No. 12/069,245.
NPD 1000 Negative Pressure Wound Therapy System, Kalypto Medical, pp. 1-4, Date: Sep. 2008.
Related Publications (1)
Number Date Country
20090177172 A1 Jul 2009 US